Merck KGaA (MKKGY) News Today $34.07 -0.57 (-1.65%) (As of 10/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Evaxion Biotech Gains Buy Rating Amid Merck Collaboration and AI-Driven Vaccine Development ProspectsSeptember 27, 2024 | markets.businessinsider.comMerck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholdersSeptember 27, 2024 | finance.yahoo.comMerck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLCSeptember 26, 2024 | markets.businessinsider.comMerck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia VirusSeptember 24, 2024 | markets.businessinsider.comMerck Gets European Panel Backing for Keytruda in Two Gynecologic CancersSeptember 20, 2024 | marketwatch.comMerck's Keytruda Secures First FDA-Approval For Rare Form Aggressive CancerSeptember 18, 2024 | benzinga.comMerck Gets First FDA Approval of Keytruda in Malignant Pleural MesotheliomaSeptember 18, 2024 | marketwatch.comMerck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage StudySeptember 17, 2024 | finance.yahoo.comMerck, Daiichi post late-stage trial win for novel lung cancer therapySeptember 17, 2024 | msn.comDaiichi Sankyo-Merck's cancer drug meets main goal in late-stage trialSeptember 17, 2024 | msn.comGilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirSeptember 16, 2024 | finance.yahoo.comMerck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer TrialSeptember 16, 2024 | markets.businessinsider.comMerck Scores Two Key Victories With Keytruda In Women's CancersSeptember 16, 2024 | msn.comMerck’s Top-Seller Cements Status in Hard-to-Treat Breast CancerSeptember 16, 2024 | bloomberg.comTen-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced MelanomaSeptember 15, 2024 | finance.yahoo.comMerck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancerSeptember 14, 2024 | seekingalpha.comMerck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancerSeptember 14, 2024 | seekingalpha.comMerck’s New Cancer Treatments Poised to Transform Standard of Care: A Strong Buy RatingSeptember 13, 2024 | markets.businessinsider.comMerck’s HPV vaccine meets key goals in Japanese studySeptember 11, 2024 | msn.comMerck stock falls on Summit cancer drug's trial resultsSeptember 10, 2024 | finance.yahoo.comA Better Drug Than Merck’s Blockbuster Keytruda? Not So FastSeptember 10, 2024 | wsj.comSummit shares surge as cancer drug tops Keytruda in head-to-head studySeptember 9, 2024 | msn.comMerck Moves EyeBio's Restoret Into Late-Stage Diabetic Macular Edema StudySeptember 4, 2024 | marketwatch.comMerck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall StreetSeptember 3, 2024 | benzinga.comMerck & Company (MRK) Receives a Buy from Evercore ISISeptember 3, 2024 | markets.businessinsider.comMerck Gets EU Approval for Keytruda Cancer TherapySeptember 3, 2024 | marketwatch.comEMD Serono: Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)August 29, 2024 | finanznachrichten.deMerck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)August 29, 2024 | finanznachrichten.deMerck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)August 29, 2024 | finance.yahoo.comMerck Gets EU Approval of Winrevair in Pulmonary Arterial HypertensionAugust 26, 2024 | marketwatch.comTop Analyst Reports for Costco, Merck & LindeAugust 24, 2024 | finance.yahoo.comMerck Insiders Sell US$11m Of Stock, Possibly Signalling CautionAugust 21, 2024 | finance.yahoo.comWeek In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million UpfrontAugust 11, 2024 | seekingalpha.comMerck discontinues late-stage trial of experimental lung cancer treatment after high number of adverse eventsAugust 9, 2024 | msn.comMerck to buy experimental drug targeting B-cell diseases for up to $1.3 billionAugust 9, 2024 | msn.comMerck Ends Trial Evaluating Lung Cancer Treatment Following Committee RecommendationAugust 8, 2024 | marketwatch.comMerck Discontinues Phase 3 KeyVibe-008 Study In Extensive-stage Small Cell Lung CancerAugust 8, 2024 | markets.businessinsider.comMerck stops experimental lung cancer drug combo trialAugust 8, 2024 | reuters.comMerck says it’s discontinuing a late-stage trial of a lung cancer treatment after high number of adverse eventsAugust 8, 2024 | msn.comKepler Capital Sticks to Their Buy Rating for Merck KGaA (0O14)August 3, 2024 | markets.businessinsider.comQ2 2024 Merck KGaA Earnings Call TranscriptAugust 2, 2024 | gurufocus.comMerck's profit in Q2 falls as semiconductor materials boost salesAugust 1, 2024 | msn.comMerck Created the World’s Biggest Drug. Now It Has to Replace It.August 1, 2024 | msn.comHere's what Wall Street expects from Merck's earnings reportAugust 1, 2024 | markets.businessinsider.comMerck KGaA Q2 Profit Down, Sales Edge Up; Maintains Recently Revised FY24 ViewAugust 1, 2024 | markets.businessinsider.comMerck Q2 Results Top Estimates, But Slashes FY24 Earnings OutlookJuly 30, 2024 | markets.businessinsider.comMerck slips as 2024 outlook disappointsJuly 30, 2024 | msn.comMerck Shares Fall After Cutting Its 2024 OutlookJuly 30, 2024 | wsj.comBig movers: NVIDIA slumps; P&G, Merck down, PayPal upJuly 30, 2024 | thestreet.comMerck tops earnings, revenue expectations but guidance mixedJuly 30, 2024 | za.investing.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere… Go here to discover the coin that could define this historic bull run with gains kicking off this mo MKKGY Media Mentions By Week MKKGY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKKGY News Sentiment▼0.320.56▲Average Medical News Sentiment MKKGY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKKGY Articles This Week▼05▲MKKGY Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 1933 Industries News Today 4Front Ventures News Today AB Science News Today Acreage News Today Acreage News Today Almirall News Today Amazonas Florestal News Today American Green News Today Avant Brands News Today Avicanna News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKKGY) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
